EMEA-001055-PIP02-21

Table of contents

Key facts

Active substance
  • Human papilloma virus type 16 E6 071-095
  • human papilloma virus type 16 E6 001-032
  • human papilloma virus type 16 E6 055-080
  • human papilloma virus type 16 E6 091-122
  • Human Papilloma Virus Type 16 E6 109-140
  • Human Papilloma Virus Type 16 E6 019-050
  • Human Papilloma Virus Type 16 E6 041-065
  • Human Papilloma Virus Type 16 E6 085-109
  • Human Papilloma Virus Type 16 E6 127-158
  • human papilloma virus type 16 E7 064-098
  • Human Papilloma Virus Type 16 E7 022-056
  • Human Papilloma Virus Type 16 E7 001-035
Therapeutic area
Oncology
Decision number
P/0251/2021
PIP number
EMEA-001055-PIP02-21
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Treatment of HPV16 positive malignancies
Route(s) of administration
Subcutaneous use
Contact for public enquiries
ISA Therapeutics B.V.

E-mail:info@isa-pharma.com
Tel. +31 713322310
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating